Linnemann, Carsten
van Buuren, Marit M
Bies, Laura
Verdegaal, Els M E
Schotte, Remko
Calis, Jorg J A
Behjati, Sam
Velds, Arno
Hilkmann, Henk
Atmioui, Dris el
Visser, Marten
Stratton, Michael R
Haanen, John B A G
Spits, Hergen
van der Burg, Sjoerd H
Schumacher, Ton N M
Article History
Received: 13 June 2014
Accepted: 18 November 2014
First Online: 22 December 2014
Change Date: 18 August 2016
Change Type: Corrigendum
Change Details: In the version of this article initially published, the article did not mention some restrictions on the availability of reagents. The following text has been added to the HTML and PDF versions of the paper: “The retroviral vectors containing BCL-6 and BCL-xL have been generated by a for-profit company, AIMM Therapeutics, which makes the plasmids available. Obtaining the plasmids requires an MTA (ExternalRef removed) that includes financial obligations.” The error has been corrected in the HTML and PDF versions of the article.
Competing interests
: The technology described in this manuscript is the subject of an EU patent application co-owned by NKI-AVL and AIMM Therapeutics B.V. Based on NKI-AVL policy on management of intellectual property, C.L., M.M.v.B., L.B. and T.N.M.S would be entitled to a portion of received royalty income. H.S. and R.S. own certificates of AIMM Therapeutics B.V. (minority stake). T.N.M.S. is a scientific advisor of AIMM Therapeutics B.V. and indirectly owns stock of AIMM Therapeutics B.V. (minority stake).